中药注射液治疗肺心病的网状Meta分析
该网状Meta分析纳入118项随机对照试验共10085例患者,比较七种中药注射液联合西药治疗肺心病的疗效。结果显示所有纳入的中药注射液联合西药均优于单用西药,其中参附注射液、参麦注射液和参芪扶正注射液联合西药可能为潜在最优治疗。滴速是临床需考虑的安全要素。
要点
- 中药注射液联合西药治疗肺心病均优于单用西药
- 参附、参麦、参芪扶正注射液联合西药可能为最优方案
- 临床使用中药注射液时需关注滴速等安全要素
核心结论
- 参附注射液联合西药、参麦注射液联合西药和参芪扶正注射液联合西药可能是肺心病的潜在最优治疗。
研究设计与样本
- 网状Meta分析,检索PubMed、Cochrane Library、EMBASE、中国生物医学文献数据库、中国知网、万方数据库和中国科技期刊数据库从建库至2019年7月14日的文献。
主要发现
- 最终纳入118项随机对照试验,共10085例患者。
- 所有符合条件的中药注射液联合西药均优于单用西药,尤其是参附注射液联合西药、参麦注射液联合西药和参芪扶正注射液联合西药。
临床怎么用
- 临床可考虑将参附注射液、参麦注射液或参芪扶正注射液联合西药用于肺心病治疗,并关注滴速等安全要素。
局限性
- 需要更大样本量和高质量的随机对照试验来确认和支持该网状Meta分析的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the severity of pulmonary heart disease and the wide utilization of Chinese herbal injections, this network meta-analysis was devised to assess the comparative efficacy of seven Chinese herbal injections (Ciwujia injection, Dazhuhongjingtan injection, Huangqi injection, Shenfu injection, Shengmai injection, Shenmai injection, and Shenqi Fuzheng injection) that were combined with Western medicines in the treatment of pulmonary heart disease. METHODS: A literature search was performed in PubMed, Cochrane Library, EMBASE, Chinese Biological Medicine Database, China National Knowledge Infrastructure, Wanfang Database, and the Chinese Scientific Journal Database from their inception to July14, 2019. This network meta-analysis was conducted in accordance with a priori eligibility criteria and methodological quality recommendations. Data analysis was performed with WinBUGS 1.4.3 and Stata 13.0 software focusing on clinical effectiveness rate, arterial blood gas analysis, hemorheology and hemodynamic indexes and right ventricular dimensions. In addition to the odds ratio or mean difference in various outcomes, the ranking probability of interventions calculated by the surface under the cumulative ranking area curve was demonstrated. The surface under the cumulative ranking area was equal to the rank of the intervention and was aimed to assess the best intervention. RESULTS: Ultimately, 118 randomized controlled trials including 10,085 patients were included. Integrating the outcome results, all eligible Chinese herbal injections plus Western medicines were superior to Western medicines alone, especially Shenfu injection+ Western medicines, Shenmai injection+ Western medicines, and Shenqi Fuzheng injection+ Western medicines. Regarding safety, the drip rate was an essential element for clinicians to consider during treatment. CONCLUSIONS: In conclusion, Shenfu injection+ Western medicines, Shenmai injection+ Western medicines and Shenqi Fuzheng injection+ Western medicines may be potential optimal treatments for pulmonary heart disease. A larger sample size and high-quality randomized controlled trials are needed to confirm and support this network meta-analysis.
引用
- Wang K, Wu J, Wang H, et al. Comparative Efficacy of Chinese Herbal Injections for Pulmonary Heart Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2020. PMID: 32457624. doi:10.3389/fphar.2020.00634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。